Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 464

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

Open access
Palanisamy, Nallasivam, Ateeq, Bushra, Kalyana-Sundaram, Shanker, Pflueger, Dorothee, Ramnarayanan, Kalpana, Shankar, Sunita, Han, Bo, Cao, Qi, Cao, Xuhong, Suleman, Khalid, Kumar-Sinha, Chandan, Dhanasekaran, Saravana M, Chen, Ying-bei, Esgueva, Raquel, Banerjee, Samprit, LaFargue, Christopher J, Siddiqui, Javed, Demichelis, Francesca, Moeller, Peter, Bismar, Tarek A, Kuefer, Rainer, Fullen, Douglas R, Johnson, Timothy M, Greenson, Joel K, Giordano, Thomas J, Tan, Patrick, Tomlins, Scott A, Varambally, Sooryanarayana, Rubin, Mark A, Maher, Christopher A, Chinnaiyan, Arul M·2010·Nature Medicine

Abstract

Although recurrent gene fusions involving erythroblastosis virus E26 transformation-specific (ETS) family transcription factors are common in prostate cancer, their products are considered 'undruggable' by conventional approaches. Recently, rare targetable gene fusions involving the anaplastic lymphoma receptor tyrosine kinase (ALK) gene, have been identified in 1–5% of lung cancers, suggesting that similar rare gene fusions may occur in other common epithelial cancers, including prostate cancer. Here we used paired-end transcriptome sequencing to screen ETS rearrangement–negative prostate cancers for targetable gene fusions and identified the SLC45A3-BRAF (solute carrier family 45, member 3–v-raf murine sarcoma viral oncogene homolog B1) and ESRP1-RAF1 (epithelial splicing regulatory protein-1–v-raf-1 murine leukemia viral oncogene homolog-1) gene fusions. Expression of SLC45A3-BRAF or ESRP1-RAF1 in prostate cells induced a neoplastic phenotype that was sensitive to RAF and mitogen-activated protein kinase kinase (MAP2K1) inhibitors. Screening a large cohort of patients, we found that, although rare, recurrent rearrangements in the RAF pathway tend to occur in advanced prostate cancers, gastric cancers and melanoma. Taken together, our results emphasize the key role of RAF family gene rearrangements in cancer, suggest that RAF and MEK inhibitors may be useful in a subset of gene fusion–harboring solid tumors and demonstrate that sequencing of tumor transcriptomes and genomes may lead to the identification of rare targetable fusions across cancer types.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.2166

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 464

Metadata

Authors
Palanisamy, N., Ateeq, B., Kalyana-Sundaram, S., Pflueger, D., Ramnarayanan, K., Shankar, S., Han, B., Cao, Q., Cao, X., Suleman, K., Kumar-Sinha, C., Dhanasekaran, S. M., Chen, Y.-B., Esgueva, R., Banerjee, S., LaFargue, C. J., Siddiqui, J., Demichelis, F., Moeller, P., Bismar, T. A., Kuefer, R., Fullen, D. R., Johnson, T. M., Greenson, J. K., Giordano, T. J., Tan, P., Tomlins, S. A., Varambally, S., Rubin, M. A., Maher, C. A., & Chinnaiyan, A. M.
Venue
Nature Medicine
Published
2010-06-06
Volume
16
Issue
7
Pages
793-798
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2029575024
Cited by
464
References
32
FWCI
21.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. https://app.cochat.ai/papers/10.1038/nm.2166
The paper
Palanisamy, N., Ateeq, B., Kalyana-Sundaram, S., Pflueger, D., Ramnarayanan, K., Shankar, S., Han, B., Cao, Q., Cao, X., Suleman, K., Kumar-Sinha, C., Dhanasekaran, S. M., Chen, Y.-B., Esgueva, R., Banerjee, S., LaFargue, C. J., Siddiqui, J., Demichelis, F., Moeller, P., . . . Chinnaiyan, A. M. (2010). Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Medicine. https://doi.org/10.1038/nm.2166

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.